İsrail - İngilizce - Ministry of Health

takeda israel ltd - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - ivig can be used in all age ranges, unless otherwise specified below.replacement therapy in:primary immunodeficiency syndromes with impaired antibody production.hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.children and adolescents (age 0-18) with congenital aids and recurrent bacterial infections.hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (hsct).immunomodulationprimary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.guillain barré syndrome.kawasaki disease.

İsrail - İngilizce - Ministry of Health

csl behring ltd., israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 100 g/l - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in• primary immunodeficiency syndromes (pid) such as: – congenital agammaglobulinaemia and hypogammaglobulinaemia – common variable immunodeficiency – severe combined immunodeficiency – wiskott-aldrich syndrome• myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections• children with congenital aids and recurrent infectionsimmunomodulation• immune thrombocytopenic purpura (itp) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count• guillain-barré syndrome• kawasaki disease• chronic inflammatory demyelinating polyneuropathy (cidp)allogeneic bone marrow transplantation

Singapur - İngilizce - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human cytomegalovirus immunoglobulin in 50mg/ml human plasma protein (igg ≥ 96%) - injection - 100 u/ml - human cytomegalovirus immunoglobulin in 50mg/ml human plasma protein (igg ≥ 96%) 100 u/ml

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v

Malta - İngilizce - Medicines Authority

octapharma (ip) limited - immunoglobulin g, human - solution for injection - immunoglobulin g, human 165 mg/ml - immune sera and immunoglobulins

Malta - İngilizce - Medicines Authority

octapharma (ip) limited - immunoglobulin g, human - solution for infusion - immunoglobulin g, human 100 mg i/ml - immune sera and immunoglobulins

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 320 mg - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Malta - İngilizce - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - immunoglobulin g, human - solution for injection - immunoglobulin g, human 165 mg/ml - immune sera and immunoglobulins